Table 1 Characteristics of patients.
Franseen n = 196 | Menghini-tip n = 113 | Reverse-bevel n = 360 | P value | |
|---|---|---|---|---|
Age, year, mean ± SD | 66.3 ± 12.0 | 62.5 ± 15.2 | 65.0 ± 12.0 | 0.039 |
Sex (Male), n (%) | 111 (56.6%) | 64 (56.6%) | 192 (53.3%) | 0.694 |
BMI, kg/m2, mean ± SD | 23.1 ± 3.5 | 22.5 ± 4.3 | 22.6 ± 3.3 | 0.202 |
Needle diameter, n (%) | < 0.001 | |||
22-gauge | 180 (91.8%) | 113 (100.0%) | 152 (42.2%) | |
25-gauge | 16 (8.2%) | 0 (0.0%) | 208 (57.8%) | |
Indication of TA, n (%) | 0.008 | |||
Suspected benign mass | 20 (10.2%) | 25 (22.1%) | 44 (12.2%) | |
Suspected malignant mass | 176 (89.8%) | 88 (77.9%) | 316 (87.8%) | |
Location of lesion, n (%) | 0.048 | |||
Uncinate process | 20 (10.2%) | 9 (8.0%) | 41 (11.4%) | |
Head | 77 (39.3%) | 51 (45.1%) | 187 (51.9%) | |
Body | 72 (36.7%) | 40 (35.4%) | 91 (25.3%) | |
Tail | 27 (13.8%) | 13 (11.5%) | 41 (11.4%) | |
Maximal size of lesion, mm, mean ± SD | 30.3 ± 10.9 | 36.3 ± 22.3 | 29.9 ± 10.5 | < 0.001 |
Initial laboratory findings, median [IQR] | ||||
WBC, mm3 | 9750.0 [6290.0–12,600.0] | 6400.0 [4700.0–7900.0] | 8700.0 [5735.0–12,500.0] | < 0.001 |
Hemoglobin, g/dL | 12.6 [11.4–13.7] | 12.6 [11.1–14.1] | 12.6 [11.5–13.6] | 0.831 |
Platelet, × 1000/mm3 | 221.0 [174.0–268.0] | 230.0 [178.0–266.0] | 222.0 [179.0–275.5] | 0.921 |
AST, IU/L | 32.5 [19.0–116.0] | 24.0 [19.0–42.0] | 33.0 [21.0–122.0] | 0.012 |
ALT, IU/L | 30.0 [15.0–126.0] | 25.0 [15.0–48.0] | 34.0 [16.5–149.5] | 0.053 |
ALP, IU/L | 101.0 [65.0–306.0] | 86.0 [62.0–165.0] | 117.5 [71.0–364.5] | 0.001 |
GGT, IU/L | 96.0 [21.0–592.0] | 48.0 [17.0–198.0] | 108.0 [24.0–634.0] | 0.002 |
Total bilirubin, mg/dL | 0.7 [0.4–6.0] | 0.6 [0.4–1.0] | 0.8 [0.4–7.1] | 0.003 |
Amylase, IU/L | 63.0 [38.0–93.0] | 62.0 [47.0–104.0] | 66.5 [44.0–114.0] | 0.608 |
